Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $294 | $278 | $269 | $279 |
| - Cash | $70 | $81 | $112 | $102 |
| + Debt | $6 | $12 | $12 | $12 |
| Enterprise Value | $230 | $209 | $169 | $189 |
| Revenue | $56 | $53 | $50 | $53 |
| % Growth | 7% | 5.1% | -5.9% | – |
| Gross Profit | $53 | $48 | $47 | $51 |
| % Margin | 94.7% | 91.5% | 93% | 95.1% |
| EBITDA | -$29 | -$33 | -$31 | -$8 |
| % Margin | -52% | -62.5% | -62.2% | -15.6% |
| Net Income | -$23 | -$27 | -$29 | -$5 |
| % Margin | -40.1% | -51.7% | -58.9% | -9.2% |
| EPS Diluted | -0.38 | -0.46 | -0.5 | -0.085 |
| % Growth | 17.4% | 8% | -491.7% | – |
| Operating Cash Flow | -$32 | -$15 | -$33 | -$2 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$32 | -$16 | -$34 | -$2 |